US/UK/Canada

Share

About Us

Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Pick a time period -
Tags ( Active)

Mertiva will be delisted from NasdaqOMX and will be listed on another marketplace

At a Board meeting on April 22, 2013 in Mertiva AB (previously Diamyd Medical AB), it was decided that the company should apply for delisting from NasdaqOMX. It was also decided that the company should be listed on another equities marketplace.The date for the delisting from NasdaqOMX will be decided together with NasdaqOMX. The intention is that the company should be listed on Aktietorget or another similar equities marketplace at the same time as the share is delisted from NasdaqOMX.

Mertiva appoints CEO

At a statutory Board meeting following an Extraordinary General Meeting on April 22, 2013 in Mertiva AB (previously Diamyd Medical AB), Andreas Bergsten was appointed as the Chief Executive Officer of the Company.Andreas Bergsten, born in 1967, is currently working as a consultant in finance and management and has, in his capacity as a consultant, primarily worked for venture capital and private equity firms. In the past, Andreas has served as CFO of four different companies and, prior to this, he was employed at Citigroup, initially as a financial analyst and subsequently as a relationship

Diamyd Medical changes name to Mertiva

At an Extraordinary General Meeting of Diamyd Medical AB on April 22, 2013, it was decided to change the Company’s name to Mertiva AB. The web address to Mertiva is www.mertiva.se.The change of name to Mertiva AB is part of the restructuring of the Diamyd Group which was decided at an Extraordinary General Meeting on April 22, 2013. The restructuring also entails distributing the subsidiary Diamyd Therapeutics AB with the diabetes operations to the shareholders and that the spun out company assumes the name Diamyd Medical AB and the web address www.diamyd.com. Mertiva (former Diamyd

Bulletin from Extraordinary General Meeting of Diamyd Medical AB

At today’s Extraordinary General Meeting of Diamyd Medical AB, a resolution was passed to approve the proposed restructuring of the Diamyd Group. The General Meeting approved the following resolutions: Change of name to Mertiva ABDiamyd Medical AB will be renamed Mertiva AB. The subsidiary Diamyd Therapeutics AB will assume the name Diamyd Medical AB. Distribution of subsidiaryThe shares in the subsidiary Diamyd Therapeutics AB (future Diamyd Medical AB) will be distributed to the shareholders. The subsidiary will own the Group’s diabetes operations and the holding in Periphagen

Information relating to the Extraordinary General Meeting of Diamyd Medical on April 22 regarding the proposed restructuring of the Diamyd Group

Provided that the Extraordinary General Meeting of Diamyd Medical AB to be held on April 22 resolves in favor of the proposed restructuring of the Diamyd Group, after which Diamyd Medical AB will be renamed Mertiva AB, the incoming Board of Directors in the future Mertiva AB plans to appoint Andreas Bergsten as the President at a statutory meeting following the General Meeting. The proposed restructuring entails, among other effects, that the subsidiary Diamyd Therapeutics AB will be distributed to shareholders and the intention is to list the company on NASDAQ OMX First North. The current

Quarterly Report II 12/13

Quarterly Report 2, Diamyd Medical AB (publ), fiscal year 2012/2013(www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)Reporting period December 1, 2012 – February 28, 2013 Group, including discontinuing operations · Group net sales amounted to MSEK 0 (0.6) · Loss before tax amounted to MSEK -6.2 (-4.2) · Liquid assets and short term investments amounted to MSEK 367 (408) as of Feb 28, 2013 First half year, September 1, 2012 – February 28, 2013 Group, including discontinuing operations · Group net sales amounted to MSEK 0.1 (0.6) · Loss before tax

Information about Summons to Extraordinary General Meeting of Diamyd Medical AB

The following summons to an Extraordinary General Meeting of Diamyd Medical AB will be available at Diamyd Medical’s website www.diamyd.com from Monday March 25, 2013. Summons to Extraordinary General Meeting of Diamyd Medical ABThe shareholders of Diamyd Medical AB (publ) are hereby summoned to an Extraordinary General Meeting at 2:00 p.m. on Monday, April 22, 2013, at Garnisonen Konferens, Karlavägen 100 in Stockholm, Sweden. AttendanceShareholders who wish to attend the Meeting must be recorded in the register of shareholders held by Euroclear Sweden AB by Tuesday April 16,

Diamyd’s major shareholders reach agreement

Shareholders in Diamyd Medical AB representing a majority of the votes in the Company have reached an agreement to distribute the parent company’s excess cash to the shareholders and to convert all shares to series B shares with equal voting power. They have further agreed that the shares in the subsidiary Diamyd Therapeutics AB shall be distributed to the shareholders and that the subsidiary shall be capitalized with SEK 50 million. The planned Extraordinary General Meeting of Diamyd Medical AB to be held on March 13, 2013 will be cancelled as a consequence of the agreement.The above

Information about Summons to Extraordinary General Meeting of Diamyd Medical AB

The following summons to an Extraordinary General Meeting of Diamyd Medical AB will be available at Diamyd Medical’s website www.diamyd.com from Wednesday February 13, 2013.Summons to Extraordinary General Meeting of Diamyd Medical AB The shareholders of Diamyd Medical AB (publ) are hereby summoned to the an Extra General Meeting on Wednesday March 13, 2013 at 2.00 pm in Garnisonen Konferens, Karlavägen 100 in Stockholm, Sweden. Attendance Shareholders who wish to attend the meeting must be recorded in the register of shareholders held by Euroclear Sweden AB by Thursday March 7,

Extraordinary General Meeting to address the proposal by a group of shareholders that Diamyd Medical enter into immediate liquidation

On February 8, 2013, a group of shareholders submitted a request in writing to the Board of Directors of Diamyd Medical that the Board convene an extraordinary General Meeting to address their proposal that Diamyd Medical enter into immediate liquidation. The shareholders claimed to represent 8,883,351 Series B shares in Diamyd, corresponding to about 21 percent of the votes and 30 percent of the total number of shares. In addition to the proposed liquidation, the group of shareholders proposes that the General Meeting elect a new Board of Directors, that the company change its name to

New clinical study with Diamyd’s diabetes vaccine

Diamyd Medical AB reports that a new clinical study with the diabetes vaccine Diamyd® is planned to start in February 2013. In the study Diamyd® will be tested in a unique combination with other drugs, aiming to potentiate the effect of the diabetes vaccine. The Company has entered into an agreement with Linköping University to conduct the researcher-initiated study. The study has been approved by the Swedish Medical Products Agency.The study, which is the first study of its kind, combines the diabetes vaccine Diamyd® with relatively high doses of vitamin D and the anti-inflammatory drug

Quarterly Report I 12/13

Quarterly Report 1, Diamyd Medical AB (publ), fiscal year 2012/2013 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)Reporting period September 1, 2012 – November 30, 2012 · Group net sales amounted to MSEK 0 (0.2) · Loss before tax amounted to MSEK -1.8 (-3.5) · Earnings per share after dilution were SEK -0.2 (-0.3) · Liquid assets and short term investments amounted to MSEK 373 (414) as of November 30, 2012 Significant events during the reporting period · Agreement was entered into for the sale of US gene therapy company and an Extraordinary General

Recombinant vaccine from Protein Sciences receives FDA approval

The US Food and Drug Administration has approved Protein Sciences Corporation’s vaccine Flublok for the prevention of seasonal influenza in adults 18 to 49 years of age. Diamyd Medical holds about 8 percent of the shares in Protein Sciences Corporation.Flublok is a recombinant protein-based seasonal influenza vaccine and the first influenza vaccine manufactured using recombinant technology that has received marketing approval by the FDA. Protein Sciences Corporation is planning to have a limited launch of the product in February 2013 with the full launch occurring in time for the 2013/14

Information about Summons to Extraordinary General Meeting of Diamyd Medical AB

The following summons to an Extraordinary General Meeting will be available at Diamyd Medical's website www.diamyd.com from Friday, December 21, 2012.Summons to Extraordinary General Meeting of Diamyd Medical AB The shareholders of Diamyd Medical AB (publ) are hereby summoned to an Extraordinary General Meeting at 2:00 p.m. on Thursday, January 31, 2013, at Kungsträdgården, Garnisonen Konferens, Karlavägen 100 in Stockholm, Sweden. AttendanceShareholders who wish to attend the Meeting must be recorded in the register of shareholders held by Euroclear Sweden AB by Friday, January 25,

Bulletin from Annual General Meeting of Diamyd Medical AB

The following items were addressed at the Annual General Meeting of Diamyd Medical AB (publ) held today: Diamyd Medical's President and CEO Peter Zerhouni gave a retrospective view of the past year and summarized the most significant events that took place during the fiscal year and after year-end. The Company's income statements and balance sheets were adopted and the Board members and the Chief Executive Officer were discharged from liability for the 2011/2012 fiscal year. The Annual General Meeting approved the Board's proposal that no dividend be paid for the 2011/2012 fiscal year.

Proposals for Board of Directors and Redemption of Shares in Diamyd Medical AB

In connection with the work of the Nomination Committee the largest shareholders of Diamyd Medical, Anders Essen-Möller, Bertil Lindkvist and Östersjöstiftelsen, have also discussed the future business and strategy of the Company. This has led to the following proposals. Proposal to redeem shares for repayment to the shareholdersIt is planned to offer the shareholders the opportunity to redeem every third share (irrespective of class of shares) against a cash payment of SEK 12 per share. This way MSEK 118.3 will be repaid to the shareholders. The proposal will be put forward at an

Information about Summons to the Annual General Meeting of Diamyd Medical AB

The following summons to the Annual General Meeting will be available at Diamyd Medical's website www.diamyd.com from Thursday November 8, 2012.Summons to the Annual General Meeting of Diamyd Medical ABThe shareholders of Diamyd Medical AB (publ) are hereby summoned to the Annual General Meeting on Thursday December 6, 2012 at 3.00 p.m. in Wenströmsalen, IVA Konferenscenter, at Grev Turegatan 16 in Stockholm, Sweden. AttendanceShareholders who wish to attend the meeting must be recorded in the register of shareholders held by Euroclear Sweden AB by Friday November 30, 2012, and must

Financial Statement 11/12

Quarterly Report Diamyd Medical AB (publ), fiscal year 2011/2012(www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)Reporting period June 1, 2012 – August 31, 2012 · Group net sales amounted to MSEK 0.1 (2.2) · Loss before tax amounted to MSEK -28.3 (-26.5) · Earnings per share after dilution were SEK -1.0 (-0.9) · The Group’s liquid assets and short term investments amounted to MSEK 380 (436) as of August 31, 2012 Full year, September 1, 2011 – August 31, 2012 · Group net sales amounted to MSEK 1.0 (280.8) · Loss before tax amounted to MSEK -51.5 (

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media